Dasatinib and nilotinib for imatinib-resistant or -intolerant chronic myeloid leukaemia: A systematic review and economic evaluation

Health Technology Assessment

Volumn 16, Issue 22, 2012, Pages 1-265

  Rogers, G ^a   Hoyle, M ^a   Thompson Coon, J ^a   Moxham, T ^a   Liu, Z ^a   Pitt, M ^a   Stein, K ^a  

^a UNIVERSITY OF EXETER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DASATINIB; IMATINIB; NILOTINIB;

ARTICLE; BLAST CELL CRISIS; CHRONIC MYELOID LEUKEMIA; COST EFFECTIVENESS ANALYSIS; CYTOGENETICS; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG RESPONSE; HEMATOLOGY; HUMAN; SYSTEMATIC REVIEW;

BLAST CRISIS; CLINICAL TRIALS AS TOPIC; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; HEALTH CARE COSTS; HUMANS; INCIDENCE; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; LEUKEMIA, MYELOID, ACCELERATED PHASE; LEUKEMIA, MYELOID, CHRONIC-PHASE; MODELS, ECONOMIC; PIPERAZINES; PROGNOSIS; PROTEIN KINASE INHIBITORS; PYRIMIDINES; QUALITY OF LIFE; THIAZOLES;

EID: 84862636359     PISSN: 13665278     EISSN: 20464924     Source Type: Journal    
DOI: 10.3310/hta16220     Document Type: Article

References (274)

1. Nowell P, Hungerford D. A minute chromosome in human chronic granulocytic leukemia. Science 1960;132:1497.
2. Rowley J. Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 1973;243:290-3.
3. Deininger MW, Goldman JM, Melo JVS. The molecular biology of chronic myeloid leukemia. Blood 2000;96:3343-56.
4. Druker BJ. Translation of the philadelphia chromosome into therapy for CML. Blood 2008;112:4808-17.
5. O'Brien S, Berman E, Bhalla K, Copelan EA, Devetten MP, Emanuel PD, et al. Chronic myelogenous leukemia. J Natl Compr Canc Netw 2007;5:474-96.
6. Sawyers CL. Chronic myeloid leukemia. N Engl J Med 1999;340:1330-40.
7. O'Dwyer ME, Mauro MJ, Blasdel C, Farnsworth M, Kurilik G, Hsieh YC, et al. Clonal evolution and lack of cytogenetic response are adverse prognostic factors for hematologic relapse of chronic phase CML patients treated with imatinib mesylate. Blood 2004;103:451-5.
8. Calabretta B, Perrotti D. The biology of CML blast crisis. Blood 2004;103:4010-22.
9. Heaney NB, Holyoake TL. Therapeutic targets in chronic myeloid leukaemia. Hematol Oncol 2007;25:66-75.
10. Kurzrock R, Gutterman JU, Talpaz M. The molecular genetics of philadelphia chromosomepositive leukemias. N Engl J Med 1988;319:990-8.
11. Hochhaus A, Kantarjian HM, Baccarani M, Lipton JH, Apperley JF, Druker BJ, et al. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. [Erratum appears in Blood 2007;110:1438.] Blood 2007;109:2303-9.
12. Guilhot F, Apperley J, Kim DW, Bullorsky EO, Baccarani M, Roboz GJ, et al. Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase. Blood 2007;109:4143-50.
13. Cortes J, Rousselot P, Kim DW, Ritchie E, Hamerschlak N, Coutre S, et al. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood 2007;109:3207-13.
14. Smith A, Roman E, Howell D, Jones R, Patmore R, Jack A, et al. The Haematological Malignancy Research Network (HMRN): a new information strategy for population based epidemiology and health service research. Br J Haematol 2010;148:739-53.
15. Sokal JE, Baccarani M, Russo D, Tura S. Staging and prognosis in chronic myelogenous leukemia. Semin Hematol 1988;25:49-61.
16. Hasford J, Pfirrmann M, Hehlmann R, Allan NC, Baccarani M, Kluin-Nelemans JC, et al. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. J Natl Cancer Inst 1998;90:850-8.
17. O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003;348:994-1004.
18. Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarijan H, Gatterman N, et al. Fiveyear follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006;355:2408-17.
19. Hughes TP, Kaeda J, Branford S, Rudzki Z, Hochhaus A, Hensley ML, et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 2003;349:1423-32.
20. Rachet B, Mitry E, Shah A, Cooper N, Coleman MP. Survival from adult leukaemia in England and Wales up to 2001. Br J Cancer 2008;99:S116-18.
21. Brenner H, Gondos A, Pulte D. Recent trends in long-term survival of patients with chronic myelocytic leukemia: disclosing the impact of advances in therapy on the population level. Haematologica 2008;93:1544-9.
22. Shah NP, Kantarjian HM, Kim DW, Rea D, Dorlhiac-Llacer PE, Milone JH, et al. Intermittent target inhibition with dasatinib 100 mg qd preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. J Clin Oncol 2008;26:3204-12.
23. Kantarjian H, Pasquini R, Hamerschlak N, Rousselot P, Holowiecki J, Jootar S, et al. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 study. Blood 2007;109:5143-50.
24. Hochhaus A. Dasatinib induces notable hematologic and cytogenetic responses in chronicphase chronic myeloid leukemia after failure of imatinib therapy. Blood 2007;110:1438.
25. Goldman JM, Apperley JF, Jones L, Marcus R, Goolden AW, Batchelor R, et al. Bone marrow transplantation for patients with chronic myeloid leukemia. N Engl J Med 1986;314:202-7.
26. Clift RA, Buckner CD, Thomas ED, Bryant E, Anasetti C, Bensinger WI, et al. Marrow transplantation for patients in accelerated phase of chronic myeloid leukemia. Blood 1994;84:4368-73.
27. Goldman JM, Szydlo R, Horowitz MM, Gale RP, Ash RC, Atkinson K, et al. Choice of pretransplant treatment and timing of transplants for chronic myelogenous leukemia in chronic phase. Blood 1993;82:2235-8.
28. Davies SM, DeFor TE, McGlave PB, Miller JS, Verfaillie CM, Wagner JE, et al. Equivalent outcomes in patients with chronic myelogenous leukemia after early transplantation of phenotypically matched bone marrow from related or unrelated donors. Am J Med 2001;110:339-446.
29. Hansen JA, Gooley TA, Martin PJ, Appelbaum F, Chauncey TR, Clift RA, et al. Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia. N Engl J Med 1998;338:962-8.
30. Silver RT, Woolf SH, Hehlmann R, Appelbaum F, Anderson J, Bennett C, et al. An evidencebased analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology. Blood 1999;94:1517-36.
31. Hochhaus A, O'Brien SG, Guilhot F, Druker BJ, Branford S, Foroni L, et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 2009;23:1054-61.
32. Talpaz M, Silver RT, Druker BJ, Goldman JM, Gambacorti-Passerini C, Guilhot F, et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 2002;99:1928-37.
33. Palandri F, Castagnetti F, Alimena G, Testoni N, Breccia M, Luatti S, et al. The long-term durability of cytogenetic responses in patients with accelerated phase chronic myeloid leukemia treated with imatinib 600 mg: the GIMEMA CML Working Party experience after a 7-year follow-up. Haematologica 2009;94:202-12.
34. Baccarani M, Saglio G, Goldman J, Hochhaus A, Simonsson B, Appelbaum F, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2006;108:1809-20.
35. Jabbour E, Kantarjian H, Jones D, Talpaz M, Bekele N, O'Brien S, et al. Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate. Leukemia 2006;20:1767-73.
36. Branford S, Rudzki Z, Walsh S, Parkinson I, Grigg A, Szer J, et al. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood 2003;102:276-83.
37. Soverini S, Martinelli G, Rosti G, Bassi S, Amabile M, Poerio A, et al. ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA working party on chronic myeloid leukemia. J Clin Oncol 2005;23:4100-9.
38. Cortes J, Jabbour E, Kantarjian H, Yin CC, Shan J, O'Brien S, et al. Dynamics of BCR-ABLkinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors. Blood 2007;110:4005-11.
39. Deininger MWN. Novel agents for chronic myeloid leukemia: from imatinib to dasatinib and nilotinib: overcoming resistance. Commun Oncol 2006;3:519-23.
40. Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001;293:876-80.
41. Hochhaus A, Kreil S, Corbin AS, La Rosee P, Muller MC, Lahaye T, et al. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 2002;16:2190-6.
42. Donato NJ, Wu JY, Stapley J, Gallick G, Lin H, Arlinghaus RB, et al. BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood 2003;101:690-8.
43. Gambacorti-Passerini C, Barni R, le Coutre P, Zucchetti M, Cabrita G, Cleris L, et al. Role of alpha1 acid glycoprotein in the in vivo resistance of human BCR-ABL(+) leukemic cells to the abl inhibitor STI571. J Natl Cancer Inst 2000;92:1641-50.
44. Jorgensen HG, Elliott MA, Allan EK, Carr CE, Holyoake TL, Smith KD. Alpha1-acid glycoprotein expressed in the plasma of chronic myeloid leukemia patients does not mediate significant in vitro resistance to STI571. Blood 2002;100:367-8.
45. Thomas J, Wang L, Clark RE, Pirmohamed M. Active transport of imatinib into and out of cells: implications for drug resistance. Blood 2004;104:3739-45.
46. Illmer T, Schaich M, Platzberger U, Freiberg-Richter J, Oelschlagel U, von Bonin M, et al. P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate. Leukemia 2004;18:401-8.
47. Dulucq S, Bouchet S, Turcq B, Lippert E, Etienne G, Reiffers J, et al. Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standarddose imatinib in chronic myeloid leukemia. Blood 2008;112:2024-7.
48. Hamdan MY, Sanders L, Oliveria S, Campbell U, Willey V, Hiji I, et al. Discontinuation and dose modification of imatinib in clinical practice. J Clin Oncol 2007;25:7045.
49. Apperley JF. Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol 2007;8:1018-29.
50. Apperley JF. Part II: management of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol 2007;8:1116-28.
51. Rousselot P, Huguet F, Rea D, Legros L, Cayuela JM, Maarek O, et al. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood 2007;109:58-60.
52. Oehler V, Gooley TA, Snyder DS, Johnston L, Lin A, Cummings CC, et al. The effects of imatinib mesylate treatment before allogeneic transplantation for chronic myeloid leukemia. Blood 2007;109:1782-9.
53. Kantarjian HM, Talpaz M, O'Brien S, Giles F, Garcia-Manero G, Faderl S, et al. Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia. Blood 2003;101:473-5.
54. Kantarjian HM, Larson RA, Guilhot F, O'Brien SG, Mone M, Rudoltz M, et al. Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase. Cancer 2009;115:551-60.
55. Schiffer CA, Hehlmann R, Larson R. Perspectives on the treatment of chronic phase and advanced phase CML and philadelphia chromosome positive ALL. Leukemia 2003;17:691-9.
56. Efficace F, Kemmler G, Vignetti M, Mandelli F, Molica S, Holzner B. Health-related quality of life assessment and reported outcomes in leukaemia randomised controlled trials -a systematic review to evaluate the added value in supporting clinical decision making. Eur J Cancer 2008;44:1497-506.
57. National Institute for Health and Clinical Excellence (NICE). Improving outcomes in haematological cancers: the manual. London: NICE; 2003.
58. Cang S, Liu D. P-loop mutations and novel therapeutic approaches for imatinib failures in chronic myeloid leukemia. J Hematol Oncol 2008;1:15.
59. Deininger MWN, Druker BJ. Circumventing imatinib resistance. Cancer Cell 2004;6:108-10.
60. Copland M, Hamilton A, Elrick LJ, Baird JW, Allan EK, Jordanides N, et al. Dasatinib (BMS- 354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood 2006;107:4532-9.
61. Jorgensen HG, Allan EK, Jordanides NE, Mountford JC, Holyoake TL. Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34 + CML cells. Blood 2007;109:4016-19.
62. Das J, Chen P, Norris D, Padmanabha R, Lin J, Moquin RV, et al. 2-Aminothiazole as a novel kinase inhibitor template. Structure-activity relationship studies toward the discovery of N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-m ethyl-4- pyrimidinyl]amino]-1, 3-thiazole-5-carboxamide (Dasatinib, BMS-354825) as a potent pan- Src kinase inhibitor. J Med Chem 2006;49:6819-32.
63. Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004;305:399-401.
64. Burgess MR, Skaggs BJ, Shah NP, Lee FY, Sawyers CL. Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance. Proc Natl Acad Sci USA 2005;102:3395-400.
65. O'Hare T, Walters DK, Stoffregen EP, Jia TP, Manley PW, Mestan J, et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 2005;65:4500-5.
66. Tokarski JS, Newitt JA, Chang CYJ, Cheng JD, Wittekind M, Kiefer SE, et al. The structure of dasatinib (BMS-354825) bound to activated ABL-kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants. Cancer Res 2006;66:5790-7.
67. European Medicines Agency. EPARS for authorised medicinal products for human use. Sprycel: European Public Assessment Report. URL: wwwemeaeuropaeu/humandocs/Humans/EPAR/sprycel/sprycelhtm (accessed 26 March 2009).
68. British Medical Association and Royal Pharmaceutical Society of Great Britain. British national formulary. No. 57. March 2009. London: BMA and RPS; 2009.
69. Weisberg E, Manley P, Mestan J, Cowan-Jacob S, Ray A, Griffin JD. AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL. Br J Cancer 2006;94:1765-9.
70. European Medicines Agency. EPARs for authorised medicinal products for human use. Tasigna: European Public Assessment Report. URL: www.emea.europa.eu/humandocs/Humans/EPAR/tasigna/tasigna.htm (accessed 26 March 2009).
71. NHS Centre for Reviews and Dissemination. Systematic reviews: CRD's guidance for undertaking reviews in health care. 3rd edn. York: NHS Centre for Reviews and Dissemination; 2009.
72. Clopper CJ, Pearson ES. The use of confidence or fiducial limits illustrated in the case of the bionmial. Biometrika 1934;26:404-13.
73. DerSimonian R, Laird N. Meta-analysis in clinical studies. Control Clin Trials 1986;7:177-88.
74. Einarson TR. Pharmacoeconomic applications of meta-analysis for single groups using antifungal onychomycosis lacquers as an example. Clin Ther 1997;19:559-69.
75. Khorashad JS, Milojkovic D, Mehta P, Anand M, Ghorashian S, Reid AG, et al. In vivo kinetics of kinase domain mutations in CML patients treated with dasatinib after failing imatinib. Blood 2008;111:2378-81.
76. Nicolini FE, Chabane K, Tigaud I, Michallet M, Magaud JP, Hayette S. BCR-ABL mutant kinetics in CML patients treated with dasatinib. Leuk Res 2007;31:865-8.
77. Soverini S, Martinelli G, Colarossi S, Gnani A, Castagnetti F, Rosti G, et al. Presence or the emergence of a F317L BCR-ABL mutation may be associated with resistance to dasatinib in philadelphia chromosome-positive leukemia. J Clin Oncol 2006;24:e51-e52.
78. Soverini S, Colarossi S, Gnani A, Castagnetti F, Rosti G, Bosi C, et al. Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL-kinase domain. Haematologica 2007;92:401-4.
79. Fabarius A, Haferlach C, Muller MC, Erben P, Lahaye T, Giehl M, et al. Dynamics of cytogenetic aberrations in Philadelphia chromosome positive and negative hematopoiesis during dasatinib therapy of chronic myeloid leukemia patients after imatinib failure. Haematologica 2007;92:834-7.
80. Kim DH, Kamel-Reid S, Chang H, Sutherland R, Jung CW, Kim HJ, et al. Natural killer or natural killer/T cell lineage large granular lymphocytosis associated with dasatinib therapy for philadelphia chromosome positive leukemia. Haematologica 2009;94:135-9.
81. Kantarjian H, Cortes J, Kim DW, Dorlhiac-Llacer P, Pasquini R, DiPersio J, et al. Phase III study of dasatinib 140 mg qd versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up. Blood 2009;113:6322-9.
82. Shah N, Pasquini R, Rousselot P, Jootar S, Holowiecki J, Countouriotis A, et al. Dasatinib (SPRYCEL (R)) vs escalated dose of imatinib (im) in patients (pts) with chronic phase chronic myeloid leukemia (CP-CML) resistant to imatinib: results of the CA180-017 START-R randomized study. Blood 2006;108:167.
83. Shah NP, Rousselot P, Pasquini R, Hamerschlak N, Holowiecki J, Gerard B, et al. Dasatinib (D) vs high dose imatinib (IM) inpatients (pts) with chronic phase chronic myeloid leukemia (CP-CML) resistant to imatinib. Results of CA180017 START-R randomized study. J Clin Oncol 2006;24:33-8S.
84. Cannell E. Dasatinib is effective in imatinib-resistant CML. Lancet Oncol 2007;8:286.
85. Kantarjian HM, Rousselot P, Pasquini R, Hamerschlak N, Holowiecki J, Dejardin D, et al. Dasatinib or high-dose imatinib for patients with chronic-phase chronic myeloid leukemia resistant to standard-dose imatinib: 2-year follow-up data from START-R (CA180-017). Blood 2007;110:736.
86. Martinelli G, Rousselot P, Robak T, Masszi T, Skotnicki A, Hellmann A. Comparison of dasatinib to high-dose imatinib in patients who experience imatinib failure: results from a randomized, phase-II study (CA180017, START-R). Haematologica 2007;92:319.
87. Schiffer CA. What if conventional-dose imatinib fails? Blood 2007;109:5068-9.
88. Rousselot P, Corm S, Paquette R, Bleickardt E, Dejardin D, Kantarjian HM, et al. Dasatinib compared with high-dose imatinib in patients with chronic myelogenous leukemia in chronic phase (Cml-Cp) after failure of standard-dose imatinib -a two-year update of the Start-R study. Haematologica 2008;93:0122.
89. Rousselot PH, Facon T, Paquette R, Bleickardt E, Dejardin D, Kantarjian HM. Dasatinib or high-dose imatinib for patients with chronic myelogenous leukemia chronic-phase (CMLCP) resistant to standard-dose imatinib: 2-year follow-up data from START-R. J Clin Oncol 2008;26:7012.
90. Hochhaus A, Kim DW, Rousselot P, Dorlhiac-Llacer PE, Milone J, Francis S, et al. Dasatinib (SPRYCEL (R)) 50 mg or 70 mg BID versus 100 mg or 140 mg QD in patients with chronic myeloid leukemia in chronic phase (CML-CP) resistant or intolerant to imatinib: results of the CA180-034 study. Blood 2006;108:166.
91. Hochhaus A, Kim DW, Rousselot P, Kantarjian H, Charbonnier A, Heim D. Dasatinib dose and schedule optimization in chronic-phase CML resistant or intolerant to imatinib: results from a randomized phase-III study (CA180034). Haematologica 2007;92(Suppl.1):359.
92. Shah NP, Kim DW, Kantarjian HM, Rousselot P, Dorlhiac-Llacer PE, Milone JH, et al. Dasatinib 50 mg or 70 mg BID compared to 100 mg or 140 mg QD in patients with CML in chronic phase (CP) who are resistant or intolerant to imatinib: one-year results of CA180034. J Clin Oncol 2007;25:7004.
93. Hochhaus A, Mueller M, Cortes JE, Kim D, Matlob Y, Ploughman L, et al. Dasatinib efficacy by dosing schedule across individual baseline BCR-ABL mutations in chronic phase chronic myelogenous leukemia (CML-CP) after imatinib failure. J Clin Oncol 2008;26:7014.
94. Hochhaus A, Muller MC, Cortes J, Kim DW, Matloub Y, Ploughman L, et al. Dasatinib efficacy after imatinib failure by dosing schedule and baseline Bcr-Abl mutation status in patients with chronic myeloid leukemia in chronic phase (Cml-Cp). Haematologica 2008;93:0933.
95. Nicaise C, Wang X, Roy A, Pfister M, Chen TT, Bleickardt E, et al. Dasatinib pharmacokinetics and exposure-response (E-R): relationships to efficacy and safety in patients with chronic myelogenous leukemia in chronic phase (Cml-Cp). Haematologica 2008;93:0559.
96. Porkka K, Khoury HJ, Paquette R, Matloub Y, Liu D, Sinha R, et al. Dasatinib 100 mg qd (QD) maintains long-term efficacy and minimizes the occurrence of pleural effusion: an analysis of 24-month data in patients with resistance, suboptimal response, or intolerance to imatinib (CA180-034). Blood 2008;112:3242.
97. Shah NP, Kim DW, Kantarjian HM, Rousselot P, Dorlhiac-Llacer P, Milone J, et al. Dasatinib dose-optimization in chronic phase chronic myeloid leukemia (CML-CP): two-year data from CA180-034 show equivalent long-term efficacy and improved safety with 100 mg qd dose. Blood 2008;112:3225.
98. Wang X, Hochhaus A, Kantarjian HM, Agrawal S, Roy A, Pfister M, et al. Dasatinib pharmacokinetics and exposure-response (E-R): relationship to safety and efficacy in patients (pts) with chronic myeloid leukemia (CML). J Clin Oncol 2008;26:3590.
99. Kantarjian H, Ottmann O, Pasquini R, Goh YT, Kim DW, Van Tornout J, et al. Dasatinib (SPRYCEL (R)) 140 mg qd (QD) vs 70 mg twice daily (BID) in patients (pts) with advanced phase chonic myeloid leukemia (ABP-CML) or ph(+) ALL who are resistant or intolerant to imatinib (im): results of the CA180-035 study. Blood 2006;108:746.
100. Pasquini R, Ottmann OG, Goh YT, Kim D, Dorlhiac Llacer PE, DiPersio JF, et al. Dasatinib 140 mg QD compared to 70 mg BID in advanced-phase CML or Ph(+) ALL resistant or intolerant to imatinib: one-year results of CA180-035. J Clin Oncol 2007;25:7025.
101. Kantarjian HM, Kim DW, Dorlhiac-Llacer P, Pasquini R, Khoroshko N, DiPersio JF, et al. Dasatinib 140 mg qd (QD) demonstrates equivalent efficacy and improved safety compared with 70 mg twice daily (BID) in patients with accelerated phase chronic myeloid leukemia (CML-AP): 2-year follow-up data from CA180-035. Blood 2008;112:3224.
102. Saglio G, Kantarjian HM, Hochhaus A, Goh YT, Masszi T, Pasquini R, et al. Dasatinib 140 mg qd (QD) demonstrates equivalent efficacy and improved safety compared with 70 mg twice daily (BID) in patients with chronic myeloid leukemia in blast phase (CML-BP): 2-year data from CA180-035. Blood 2008;112:3226.
103. Kantarjian H, Giles F, Wunderle L, Bhalla K, O'Brien S, Wassmann B, et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 2006;354:2542-51.
104. Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, Paquette R, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006;354:2531-41.
105. Hochhaus A, Baccarani M, Deininger M, Apperley JF, Lipton JH, Goldberg SL, et al. Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia 2008;22:1200-6.
106. Kantarjian HM, Giles F, Gattermann N, Bhalla K, Alimena G, Palandri F, et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood 2007;110:3540-6.
107. le Coutre CP, Ottmann OG, Giles F, Kim DW, Cortes J, Gattermann N, et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia. Blood 2008;111:1834-9.
108. Tojo A, Usuki K, Urabe A, Maeda Y, Kobayashi Y, Jinnai I, et al. A Phase I/II study of nilotinib in Japanese patients with imatinib-resistant or -intolerant Ph+ CML or relapsed/ refractory Ph+ ALL. Int J Hematol 2009;89:679-88.
109. Sakamaki H, Ishizawa K, Taniwaki M, Fujisawa S, Morishima Y, Tobinai K, et al. Phase I/2 clinical study of dasatinib in Japanese patients with chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia. Int J Hematol 2009;89:332-41.
110. Giles FG, Ottmann OT, Cortes J, Wassmann B, Bhalla K, Jones D, et al. AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has significant activity in imatinib-resistant Bcr-Abl positive chronic myeloid leukemia (CML). Br J Haematol 2005;129:8.
111. Singer JB, Shou Y, Giles F, Kantarjian HM, Hsu Y, Robeva AS, et al. UGT1A1 promoter polymorphism increases risk of nilotinib-induced hyperbilirubinemia. Leukemia 2007;21:2311-15.
112. La RP, Holm-Eriksen S, Konig H, Hartel N, Ernst T, Debatin J, et al. Phospho-CRKL monitoring for the assessment of BCR-ABL activity in imatinib-resistant chronic myeloid leukemia or Ph+ acute lymphoblastic leukemia patients treated with nilotinib. Haematologica 2008;93:765-9.
113. Chu SC, Tang JL, Li CC. Dasatinib in chronic myelogenous leukemia. N Engl J Med 2006;355:1062-3.
114. Sawyers CL, Talpaz M, Bleickardt E. Dasatinib in chronic myelogenous leukemia -reply. N Engl J Med 2006;355:1063-4.
115. Cortes J, Sawyers CL, Kantarjian HM, Shah NP, Paquette R, Bleickardt E, et al. Dasatinib is associated with durable treatment responses in chronic phase chronic myeloid leukemia: long-term follow-up from the phase I trial (Ca180002). Haematologica 2008;93:0119.
116. Ottmann OG, Martinelli G, Dombret H, Kantarjian H, Hochhaus A, Simonsson B, et al. A phase II study of dasatinib in patients with chronic myeloid leukemia (CML) in lymphoid blast crisis or philadelphia-chromosome positive acute lymphoblastic leukemia (Ph plus ALL) who are resistant or intolerant to imatinib: the 'START-L' CA180015 study. Blood 2005;106:42.
117. Talpaz M, Rousselot P, Kim DW, Guilhot F, Corm S, Bleickardt E, et al. A phase II study of dasatinib in patients with chronic myeloid leukemia (CML) in myeloid blast crisis who are resistant or intolerant to imatinib: first results of the CA180006 'START-B' study. Blood 2005;106:40.
118. Chromik J, Pfeifer H, Wunderle L, Schoch N, Wassmann B, Brueck P, et al. Sustained molecular responses to dasatanib (SPRYCEL (R)) in patients with Philadelphia chromosomepositive (Ph(+)) acute lymphoblastic leukemia (ALL) or lymphoid blast phase (LyBP) chronic myeloid leukemia after imatinib (IM) failure: a single-center experience. Blood 2006;108:285.
119. Cortes JE, Kim DW, Rosti G, Rousselot P, Bleickardt E, Zink R, et al. Dasatinib (D) in patients (pts) with chronic myelogenous leukemia (CML) in myeloid blast crisis (MBC) who are imatinib-resistant (IM-R) or IM-intolerant (IM-I): results of the CA180006 'START-B' study. J Clin Oncol 2006;24:344S.
120. Martinelli G, Hochhaus A, Coutre S, Apperley JF, Shah N, Gollerkeri A, et al. Dasatinib (SPRYCEL (R)) efficacy and safety in patients (pts) with chronic myelogenous leukemia in lymphoid (CML-LB) or myeloid blast (CML-MB) phase who are imatinib-resistant (Im-r) or -intolerant (Im-i). Blood 2006;108:745.
121. Ganibacoiti C, Cortes J, Kim DW, Dombret H, Zhu C, Van Tornout JMA, et al. Efficacy and safety of dasatinib in patients with chronic myeloid leukemia in blast phase whose disease is resistant or intolerant to imatinib: 2-year follow-up data from the START program. Blood 2007;110:472.
122. Ottmann O, Dombret H, Martinelli G, Simonsson B, Guilhot F, Larson RA, et al. Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study. Blood 2007;110:2309-15.
123. Cortes J, Kim DW, Raffoux E, Martinelli G, Ritchie E, Roy L, et al. Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase. Leukemia 2008;22:2176-83.
124. Porkka K, Koskenvesa P, Lundan T, Rimpilainen J, Mustjoki S, Smykla R, et al. Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system philadelphia chromosome-positive leukemia. Blood 2008;112:1005-12.
125. Saglio G, Dombret H, Rea D, Corm S, Cortes J, Kim DW, et al. Dasatinib efficacy in patients with imatinib-resistant/-intolerant chronic myeloid leukemia in blast phase: 24-month data from the Start Program. Haematologica 2008;93:abstract 0880.
126. Guilhot F, Apperley JF, Shah N, Kim DW, Grigg A, Cheng S, et al. A phase II study of dasatinib in patients with accelerated phase chronic myeloid leukemia (CML) who are resistant or intolerant to imatinib: first results of the CA180005 'START-A' study. Blood 2005;106:39.
127. Cortes J, Kim DW, Guilhot F, Rosti G, Silver RT, Gollerkeri A, et al. Dasatinib (SPRYCEL (R)) in patients (pts) with chronic myelogenous leukemia in accelerated phase (AP-CML) that is imatinib-resistant (im-r) or -intolerant (im-i): updated results of the CA180-005 'START-A' phase II study. Blood 2006;108:2160.
128. Talpaz M, Apperley JF, Kim DW, Silver RT, Bullorsky EO, Cheng S, et al. Dasatinib (D) in patients with accelerated phase chronic myeloid leukemia (AP-CML) who are resistant or intolerant to imatinib: results of the CA180005 'START-A' study. J Clin Oncol 2006;24:343S.
129. Guilhot F, Apperley JF, Kim DW, Kosti G, Yuan X, Van Tomout JMA, et al. Efficacy of dasatinib in patients with accelerated-phase chronic myelogenous leukemia with resistance or intolerance to imatinib: 2-year follow-up data from START-A (CA180-005). Blood 2007;110:470.
130. O'Brien S. Dasatinib in accelerated phase. Blood 2007;109:4110.
131. Rea D, Dombret H, Kim DW, Rosti G, Roy L, Garzon FT, et al. Dasatinib efficacy in patients with imatinib-resistant/-intolerant chronic myeloid leukemia in accelerated phase: 24-month data from START-A. Haematologica 2008;93:391.
132. Rea D, Dombret H, Kim DW, Rosti G, Roy L, Garzon FT, et al. Dasatinib efficacy in patients with imatinib-resistant/-intolerant chronic myeloid leukemia in accelerated phase: 24-month data from Start-A. Haematologica 2008;93:0982.
133. Hochhaus A, Baccarani M, Sawyers C, Nagler A, Facon T, Goldberg SL, et al. Efficacy of dasatinib in patients with chronic phase Philadelphia chromosome-positive CML resistant or intolerant to imatinib: first results of the CA180013 'START-C' phase II study. Blood 2005;106:41.
134. Baccarani M, Kantarjian HM, Apperley JF, Lipton JH, Druker B, Countouriotis A, et al. Efficacy of dasatinib (SPRYCEL (R)) in patients (pts) with chronic phase chronic myelogenous leukemia (CP-CML) resistant to or intolerant of imatinib: updated results of the CA180013 'START C' phase II study. Blood 2006;108:164.
135. Hochhaus A, Kantarjian H, Baccarani M, Cervantes F, Facon T, Goldberg S, et al. Dasatinib in patients with chronic phase chronic myeloid leukemia (CP-CML) who are resistant or intolerant to imatinib: results of the CA180013 'START-C' Study. J Clin Oncol 2006;24:339S.
136. Hochhaus A, Kantarjian H, Baccarani M, Cervantes F, Facon T, Goldberg S, et al. Dasatinib in patients with chronic phase chronic myeloid leukemia (CP-CML) who are resistant or intolerant to imatinib: results of the CA180013 'START-C' Study. J Clin Oncol 2006;24(Suppl. 18):6508.
137. Guilhot F, Apperley J, Facon T, Niederwieser D, Gambacorti C, Fischer T, et al. Dasatinib induces durable cytogenetic responses in patients with chronic-phase CML with resistance or intolerance to imatinib: updated results of the CA180013 (START-C) study. Haematologica 2007;92:128.
138. Mueller MC, Erben P, Ernst T, Giehl M, Schenk T, Hoffmann J, et al. Molecular response according to type of preexisting BCR-ABL mutations after second Line dasatinib therapy in chronic phase CML patients. Blood 2007;110:319.
139. Stone RM, Kantarjian HM, Baccarani M, Lipton JH, Hughes T, Ezzeddine R, et al. Efficacy of dasatinib in patients with chronic-phase chronic myelogenous leukemia with resistance or intolerance to imatinib: 2-year follow-up data from START-C (CA180-013). Blood 2007;110:734.
140. Baccarani M, Rosti G, Saglio G, Cortes J, Stone R, Niederwieser DW, et al. Dasatinib time to and durability of major and complete cytogenetic response (MCyR and CCyR) in patients with chronic myeloid leukemia in chronic phase (CML-CP). Blood 2008;112:450.
141. Cervantes F, Baccarani M, Lipton J, Matloub Y, Sinha S, Stone R, et al. Dasatinib longterm efficacy in patients with chronic myeloid leukemia in chronic phase (CML-CP) with resistance or intolerance to imatinib: a 2-year update of the START-C Study. Haematologica (EHA Annual Meeting Abstracts) 2008;93:372.
142. Goldman JM, Druker BJ. Chronic myeloid leukemia: current treatment options. Blood 2001;98:2039-42.
143. Cortes J, Mauro M, O'Brien S, Borthakur G, Wierda W, Matloub Y, et al. The vast majority of CML-CP patients treated with dasatinib (70 mg BID) who progress after long-term follow-up (24 mo) remain in chronic-phase. Blood 2008;112:4265.
144. Deininger MWN, Mauro MJ, Matloub Y, Sinha R, Ploughman L, Liu D, et al. Prevalence of T315I, dasatinib-specific resistant mutations (F317L, V299L, and T315A), and nilotinibspecific resistant mutations (P-loop and F359) at the time of imatinib resistance in chronicphase chronic myeloid leukemia (CP-CML). Blood 2008;112:3236.
145. Hochhaus A, Baccarani M, Deininger M, Apperley JF, Lipton JH, Goldberg SL, et al. Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia 2008;22:1200-6.
146. Hochhaus A, Muller MC, Radich J, Branford S, Hanfstein B, Rousselot P, et al. Dasatinibassociated major molecular responses are rapidly achieved in patients with chronic myeloid leukemia in chronic phase (CML-CP) following resistance, suboptimal response, or intolerance on imatinib. Blood 2008;112:1095.
147. Mauro MJ, Baccarani M, Cervantes F, Lipton JH, Matloub Y, Sinha R, et al. Dasatinib 2-year efficacy in patients with chronic-phase chronic myelogenous leukemia (CML-CP) with resistance or intolerance to imatinib (START-C). J Clin Oncol 2008;26:7009.
148. Kantarjian HM, Gattermann N, O'Brien SG, Bhalla K, Hochhaus A, Cervantes F, et al. A phase II study of AMN107, a novel inhibitor of Bcr-Abl, administered to imatinib resistant and intolerant patients (pts) with chronic myelogenous leukemia (CML) in chronic phase (CP). J Clin Oncol 2006;24:345S.
149. le Coutre P, Bhalla K, Giles F, Baccarani M, Ossenkoppele GJ, Hochhaus A, et al. A phase II study of nilotinib, a novel tyrosine kinase inhibitor administered to imatinib-resistant and -intolerant patients with chronic myelogenous leukemia (CML) in chronic phase (CP). Blood 2006;108:165.
150. Cortes J, Jabbour E, Hochhaus A, le Coutre P, Baccarani M, Bhalla KN, et al. Nilotinib is associated with minimal cross intolerance to imatinib in patients with imatinib-intolerant philadelphia-positive (Ph+) chronic myelogenous leukemia (CML) in either chronic phase (CP) or accelerated phase (AP). Blood 2007;110:1040.
151. Hochhaus A, Giles FJ, le Coutre P, Baccarani M, Gattertnann N, Bhalla KN, et al. Safety, and efficacy of nilotinib dose escalation 600 mg BID in patients (pts) with imatinib-resistant or -intolerant chronic myeloid leukemia (CML) in chronic phase (CP). Blood 2007;110:1038.
152. Hughes T, Saglio G, Martinelli G, Kim DW, Soverini S, Mueller M, et al. Responses and disease progression in CML-CP patients treated with nilotinib after imatinib failure appear to be affected by the BCR-ABL mutation status and types. Blood 2007;110:320.
153. Kantarjian HM, Hochhaus A, Cortes J, Martinelli G, Bhalla KN, Giles FJ, et al. Nilotinib is highly active and safe in chronic phase chronic myelogenous leukemia (CML-CP) patients with imatinib-resistance or intolerance. Blood 2007;110:735.
154. Martinelli G, Rosti G, le Coutre P, Bhalla K, Giles F, Ossenkoppele G, et al. A phase II study of nilotinib, a novel tyrosine kinase inhibitor administered to imatinib-resistant and -intolerant patients with Philadelphia-positive chronic myelogenous leukemia in chronic phase. Haematologica 2007;92:0555.
155. Mueller MC, Branford S, Radich J, Kim DW, Martinelli G, Saglio G, et al. Response dynamics to nilotinib depend on the type of BCR-ABL mutations in patients with chronic myelogenous leukemia (CML) after imatinib failure. J Clin Oncol 2007;25:7024.
156. Rosti G, Hochhaus A, le Coutre P, Baccarani M, Bhalla K, Ossenkoppele G, et al. Nilotinib isassociated with minimal cross intoleranceto imatinib in patients with imatinib-intolerant Philadelphia-positive chronic myelogenous leukemia in either chronic phase or accelerated phase. Haematologica 2007;92:0860.
157. Rosti G, le Coutre P, Bhalla K, Giles F, Ossenkoppele G, Hochhaus A, et al. A phase II study of nilotinib administered to imatinib resistant and intolerant patients with chronic myelogenous leukemia (CML) in chronic phase (CP). J Clin Oncol 2007;25:7007.
158. Hochhaus A, Kantarjian HM, Baccarani M, le Coutre P, Haque A, Gallagher N, et al. Minimal cross-intolerance between nilotinib and imatinib in patients with imatinibintolerant chronic myelogenous leukaemia (Cml) in chronic phase (Cp) or accelerated phase (Ap). Haematologica 2008;93:O141.
159. Jabbour E, Kantarjian HM, Baccarani M, le Coutre PD, Haque A, Gallagher NJ, et al. Minimal cross-intolerance between nilotinib and imatinib in patients with imatinibintolerant chronic myeloid leukemia in chronic phase (CML-CP) or accelerated phase (CML-AP). Blood 2008;112:3215.
160. Kantarjian HM, Giles FJ, Bhalla KN, Larson RA, Gatterman N, Ottmann OG, et al. Nilotinib in chronic myelogenous leukaemia in chronic phase (Cml-Cp) patients with imatinibresistance or intolerance: updated phase 2 results. Haematologica 2008;93:0883.
161. Kantarjian HM, Giles FJ, Hochhaus A, Bhalla KN, Ossenkoppele GJ, Gattermann N, et al. Nilotinib in patients with imatinib-resistant or -intolerant chronic myelogenous leukemia in chronic phase (CML-CP): updated phase II results. J Clin Oncol 2008;26:7010.
162. Lipton JH, le Coutre PD, Wang J, Yang M, Szczudlo T, Giles F. Nilotinib in elderly chronic myeloid leukemia patients in chronic phase (CML-CP) with imatinib resistance or intolerance: efficacy and safety analysis. Blood 2008;112:3233.
163. Radich J, Kim DW, Martinelli G, Soverini S, Branford S, Mueller M, et al. Response to nilotinib in chronic myelogenous leukemia patients in chronic phase (Cml-Cp) according to Bcr-Abl mutations at baseline. Haematologica 2008;93:O137.
164. Saglio G, Radich J, Kim D, Martinelli G, Branford S, Mueller M, et al. Response to nilotinib in chronic myelogenous leukemia patients in chronic phase (CML-CP) according to BCR-ABL mutations at baseline #7060. J Clin Oncol 2008;26:7060.
165. Clark R, le Coutre P, Giles FJ, Hocchaus A, Haque A, Gallagher N, et al. Nilotinib in chronic myeloid leukaemia patients in chronic phase (CML-CP) with imatinib resistance or intolerance: follow-up results of a phase 2 study. Br J Haematol 2009;145:101.
166. le Coutre P, Gattermann N, Hochhaus A, Larson R, Weitzman A, Haque A, et al. A phase II study of nilotinib administered to imatinib resistant or intolerant patients with chronic myelogenous leukemia (CML) in accelerated phase (AP). J Clin Oncol 2007;25:7026.
167. le Coutre P, Giles FJ, Apperley J, Ottmann OG, Gattermann N, O'Brien SG, et al. Nilotinib is safe and effective in accelerated phase chronic myelogenous leukemia (CML-AP) patients with imatinib resistance or intolerance. Blood 2007;110:471.
168. le Coutre P, Larson R, Kantarjian H, Gattermann N, Hochhaus A, Haque A, et al. A phase II study of nilotinib,a noveltyrosine kinase inhibitor administered to imatinib-resistant or -intolerant patients with Philadelphia positive chronic myelogenous leukemia in accelerated phase. Haematologica 2007;92:0557.
169. Saglio G, Kim DW, Hochhaus A, Soverini S, Erben P, Branford S, et al. Correlation of clinical response to nilotinib with BCR-ABL mutation status in advanced phase chronic myelogenous leukemia (CML-AP) patients with imatinib-resistance or intolerance. Blood 2007;11:1940.
170. Alexander W, le Coutre CP. American Society of Hematology 49th Annual Meeting: nilotinib (Tasigna) in chronic myelogenous leukemia. P and T 2008;33:113,117.
171. Apperley J, le Coutre P, Giles FJ, Ottmann OG, Larson RA, Haque A, et al. Nilotinib in accelerated phase chronic myelogenous leukaemia (CML-AP) patients with imatinibresistance or -intolerance: update of a phase 2 study. Br J Haematol 2008;141:106.
172. Kantarjian HM, Giles F, Bhalla KN, Larson RA, Gattermann N, Ottmann OG, et al. Nilotinib in chronic myeloid leukemia patients in chronic phase (CMLCP) with imatinib resistance or intolerance: 2-year follow-up results of a phase 2 study. Blood 2008;112:3238.
173. le Coutre P, Giles FJ, Apperley J, Ottmann OG, Larson RA, Haque A, et al. Nilotinib in accelerated phase chronic myelogenous leukemia (CML-AP) patients with imatinibresistance or -intolerance: update of a phase II study. J Clin Oncol 2008;26:7050.
174. le Coutre P, Giles FJ, Hochhaus A, Apperley J, Ossenkoppele G, Haque A, et al. Nilotinib in imatinib-resistant or -intolerant patients with chronic myelogenous leukaemia in accelerated phase (Cml-Ap): update of a phase 2 study. Haematologica 2008;93:0118.
175. le Coutre PD, Giles F, Hochhaus A, Apperley JF, Ossenkoppele G, Haque A, et al. Nilotinib in chronic myeloid leukemia patients in accelerated phase (CML-AP) with imatinib resistance or intolerance: 2-year follow-up results of a phase 2 study. Blood 2008;112:3229.
176. Apperley JF, Cortes JE, Kim DW, Roy L, Roboz GJ, Rosti G, et al. Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START A trial. J Clin Oncol 2009;27:3472-9.
177. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled studies. JAMA 1995;273:408-12.
178. Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al. Does quality of reports of randomised studies affect estimates of intervention efficacy reported in meta-analyses? Lancet 1998;352:609-13.
179. Kjaergard LL, Villumsen J, Gluud C. Quality of randomised clinical studies affects estimates of intervention efficacy. Abstracts for Workshops and Scientific Sessions, 7th International Cochrane Colloquium, Rome, Italy, 1999.
180. Juni P, Altman DG, Egger M. Systematic reviews in health care: assessing the quality of controlled clinical studies. BMJ 2001;323:42-6.
181. Schulz KF. Subverting randomization in controlled studies. JAMA 1995;274:1456.
182. Jabbour E, Kantarjian HM, Jones D, Shan J, O'Brien S, Reddy N, et al. Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy. Blood 2009;113:2154-60.
183. Dalziel K, Round A, Stein K, Garside R, Castelnuovo E, Payne L. Do the findings of case series studies vary significantly according to methodological characteristics? Health Technol Assess 2005;9(2).
184. Bristol-Myers Squibb Pharmaceuticals Ltd. Dasatinib (Sprycel) for the treatment of adults with chronic, accelerated or blast phase CML with resistance or intolerance to prior therapy including imatinib. Multiple technology appraisal submission to the National Institute for Health and Clinical Excellence. 2009.
185. Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629-34.
186. National Cancer Institute's Common Toxicity Criteria v3.0. 2006. URL: http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.h tm (accessed December 2008).
187. Quintas-Cardama A, Kantarjian HM, Nicaise C, Garcia-Manero G, O'Brien S, Ravandi F, et al. Cytopenias in patients (pts) with chronic myelogenous leukemia (CML) in chronic phase (CP) treated with dasatinib (SPRYCEL (R)): clinical features and management, including outcome after hematopoietic growth factor therapy. Blood 2006;108:2163.
188. Aribi A, Kantarjian H, Koller C, Thomas D, Faderl S, Garcia-Manero G, et al. The Effect of interleukin 11 on thrombopenia associated with tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia. Cancer 2008;113:1338-43.
189. Bergeron A, Rea D, Levy V, Picard C, Meignin V, Tamburini J, et al. Lung abnormalities after dasatinib treatment for chronic myeloid leukemia: a case series. Am J Respir Crit Care Med 2007;176:814-18.
190. Quintas-Cardama A, Kantarjian H, O'Brien S, Borthakur G, Bruzzi J, Munden R, et al. Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J Clin Oncol 2007;25:3908-14.
191. Quintas-Cardama A, Kantarjian HM, Munden R, Talpaz M, Bruzzi J, O'Brien S, et al. Pleural effusion in patients (pts) with chronic myelogenous leukemia (CML) treated with dasatinib after imatinib failure. Blood 2006;108:2164.
192. de Lavallade H, Punnialingam S, Milojkovic D, Bua M, Khorashad JS, Gabriel IH, et al. Pleural effusions in patients with chronic myeloid leukaemia treated with dasatinib may have an immune-mediated pathogenesis. Br J Haematol 2008;141:745-7.
193. Punnialingam S, De Lavallade H, Milojkovic D, Marco B, Khorashad JS, Goldman JM, et al. Pleural effusions associated with use of dasatinib in chronic myeloid leukemia may have an auto-immune pathogenesis. Blood 2007;110:2945.
194. Rousselot PH, Bergeron A, Rea D, Levy V, Picard C, Meignin V, et al. Pleural and pulmonary events in patients treated with dasatinib for chronic myeloid leukemia in chronic phase. Haematologica 2007;92:0546.
195. Quintas-Cardama A, Kantarjian H, Ravandi F, O'Brien S, Thomas D, Vidal-Senmache G, et al. Bleeding diathesis in patients with chronic myelogenous leukemia receiving dasatinib therapy. Cancer 2009;115:2482-90.
196. Quintas-Cardama A, Kantarjian H, Ravandi F, Burger J, Borthakur G, Cortes J. Bleeding diathesis in patients (pts) with chronic myelogenous leukemia receiving dasatinib therapy. Blood 2007;110:2958.
197. Holstein SA, Stokes JB, Hohl RJ. Renal failure and recovery associated with secondgeneration Bcr-Abl kinase inhibitors in imatinib-resistant chronic myelogenous leukemia. Leuk Res 2009;33:344-7.
198. Garcia-Munoz R, Galar A, Moreno C, Rodriguez-Otero P, Panizo-Morgado E, Ponz- Sarvise M, et al. Parvovirus B19 acute infection and a reactivation of cytomegalovirus and herpesvirus 6 in a chronic myeloid leukemia patient during treatment with dasatinib (BMS- 354825). Leuk Lymphoma 2007;48:2461-4.
199. Radaelli F, Bramanti S, Fantini N, Fabio G, Greco I, Lambertenghi-Deliliers G. Dasatinibrelated alveolar pneumonia responsive to corticosteroids. Leuk Lymphoma 2006;47:1180-1.
200. Rea D, Bergeron A, Fieschi C, Bengoufa D, Oksenhendler E, Dombret H. Dasatinib-induced lupus. Lancet 2008;372:713-14.
201. Assouline S, Laneuville P, Gambacorti-Passerini C. Panniculitis during dasatinib therapy for imatinib-resistant chronic myelogenous leukemia. N Engl J Med 2006;354:2623-4.
202. Bonvin A, Mesnil A, Nicolini FE, Cotte L, Michallet M, Descotes J, et al. Dasatinib-induced acute hepatitis. Leuk Lymphoma 2008;49:1630-2.
203. Caocci G, Atzeni S, Orru N, Azzena L, Martorana L, Littera R, et al. Gynecomastia in a male after dasatinib treatment for chronic myeloid leukemia. Leukemia 2008;22:2127-8.
204. Leiba M, Shimoni A, Guilhot F, Martineau G, Renaud M, Francois S, et al. No evidence for increased transplant related complications in Ph plus chronic myelogenous leukemia and acute lymphoblastic leukemia with prior treatment with Dasatinib. Blood 2006;108:2975.
205. Novartis Pharmaceuticals UK Ltd. Nilotinib for the treatment of adults with chronic myeloid leukaemia in the chronic phase or accelerated phase with resistance or intolerance as well as resistance to prior therapy, including imatinib. 2009.
206. Food and Drug Administration. Tasigna (nilotinib) capsules. URL: www.accessdata.fda.gov/drugsatfda_docs/label/2007/022068lbl.pdf (accessed 15 December 2009).
207. Breccia M, Muscaritoli M, Gentilini F, Latagliata R, Carmosino I, Fanelli FR, et al. Impaired fasting glucose level as metabolic side effect of nilotinib in non-diabetic chronic myeloid leukemia patients resistant to imatinib. Leuk Res 2007;31:1770-2.
208. Kaune KM, Baumgart M, Gesk S, Mitteldorf C, Baesecke J, Glass B, et al. Bullous sweet syndrome in a patient with t(9;22)(q34;q11)-positive chronic myeloid leukemia treated with the tyrosine kinase inhibitor nilotinib: interphase cytogenetic detection of BCR-ABLpositive lesional cells. Arch Dermatol 2008;144:361-4.
209. Sambrook JC, Zou D, Taylor MJ, Davis CC, Joyeux A, Levy AR. Cost-effectiveness analysis in Canada of dasatinib versus imatinib for the treatment of chronic myelogenous leukemia in patients with imatinib resistance. Blood 2007;110:3328.
210. Logman JFS, Taylor MJ, Neumann K, Kutikova L, Cerri KH, Van Houc BA, et al. Cost-utility analysis of dasatinib in patients after first-line failure of imatinib in chronic myeloid leukemia (CML) in Austria. Value Health 2007;10:A325.
211. Juarez-Garcia A, Zapata L, Vega G, Idrovo J, Rivas R, Kramis JL, et al. The cost and cost effectiveness of dasatinib (Sprycel) therapy for the management of imatinib resistant and intolerant patients with chronic myeloid leukemia (CML) in Mexico. Value Health 2008;11:A157.
212. Brosa M, Taylor MJ, Staginnus U, Meno Duran A, Cerri KH, Cervantes F. Cost-effectiveness of dasatinib vs imatinib 800 mg qd in patients with imatinib-resistant chronic myeloid leukemia in Spain. Value Health 2007;10:A283.
213. Quissak C, Litalien G, Alves MR. Cost-effectiveness analysis of dasatinib for the treatment of imatinib resistant or intolerant CML patients in Brazil. Value Health 2008;11:A64.
214. Jewitt K, Pilgrim H, Ward S. A cost-utility analysis of nilotinib for CML patients who have become resistant to imatinib. Br J Haematol 2008;141:105.
215. Pilgrim H, Jewitt K, Ward S. A cost-utility analysis of nilotinib for CML patients who have become resistant to imatinib. Blood 2007;110:5175.
216. Mataveli FD, Feng W, Calabro A, Mendes W, Hungria VS The treatment cost to achieve a complete cytogenetic response in imatinib resistant chronic phase (CP) chronic myelogenous leukemia (CML) patients: nilotinib vs. dasatinib. Blood 2007;110:3327.
217. Botteman M, Stephens J, Carpiuc K, Feng W. Projecting the long-term quality-adjusted. survival of patients with imatinib-resistant chronic myelogenous leukemia in chronic phase receiving nilotinib, dasatinib dose escalation imatinib, or palliative care: an essential element for cost-effectiveness analysis. Blood 2007;110:4585.
218. Scottish Medicines Consortium. Nilotinib, 200 mg capsules (Tasigna). 2008. URL: www.scottishmedicines.org.uk/files/nilotinib_200mg_capsules_Tasigna_FINA L_Feb_2008_amended_May_2008_for_Website.pdf (accessed December 2008).
219. Scottish Medicines Consortium. Dasatinib, 20 mg, 50 mg, 70 mg tablets (Sprycel). 2007. URL: www.scottishmedicines.org.uk/files/dasatanib__Sprycel__CML_FINAL_April_2 007__amended_010507__for_website.pdf (accessed December 2008).
220. National Institute for Health and Clinical Excellence. Guide to the methods of technology appraisal. London: National Institute for Health and Clinical Excellence; 2004.
221. Philips Z, Bojke L, Sculpher M, Claxton K, Golder S. Good practice guideliens for decision analytic modelling in health technology assessment: a review and consolidation of quality assessment. Pharmacoeconomics 2006;24:355-71.
222. National Institute for Health and Clinical Excellence. Guide to the methods of technology appraisal. London: National Institute for Health and Clinical Excellence; 2008.
223. Kantarjian H, O'Brien S, Talpaz M, Borthakur G, Ravandi F, Faderl S, et al. Outcome of patients with philadelphia chromosome-positive chronic myelogenous leukemia postimatinib mesylate failure. Cancer 2007;109:1556-60.
224. Zonder JA, Pemberton P, Brandt H, Mohamed AN, Schiffer CA. The effect of dose increase of imatinib mesylate in patients with chronic or accelerated phase chronic myelogenous leukemia with inadequate hematologic or cytogenetic response to initial treatment. Clin Cancer Res 2003;9:2092-7.
225. Reed SD, Anstrom KJ, Ludmer JA, Glendenning GA, Schulman KA. Cost-effectiveness of imatinib versus interferon-alpha plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia. Cancer 2004;101:2574-83.
226. Dalziel K, Round A, Garside R, Stein K. Cost effectiveness of imatinib compared with interferon-alpha or hydroxycarbamide for first-line treatment of chronic myeloid leukaemia. Pharmacoeconomics 2005;23:515-26.
227. Curtis L. Unit costs of health and social care. 2007. URL: www.pssru.ac.uk/pdf/uc/uc2007/uc2007.pdf (accessed December 2008).
228. MIMS. 2009. URL: www.mims.co.uk (accessed December 2008).
229. Levy A. Utility values for health states for chronic myelogenous leukemia from laypersons in the United States, Australia, United Kingdom and Canada. Final study report. 2008.
230. Levy A, Szaba SM, Taberrer M, Davis C. Utility values for health states for chronic myelogenous leukaemia (CML): estimates from laypersons in Australia, the United Kingdom (UK) and Canada. Dublin; ISPOR: 2007.
231. McLeod C, Bagust A, Boland A, Hockenhull J, Dundar Y, Proudlove C, et al. Erlotinib for the treatment of relapsed non-small cell lung cancer. Health Technol Assess 2009;13(Suppl. 1):41-7.
232. Government Actuary's Department. Life Tables. URL: www.gad.govsuk/Demography%20Data/Life%20Tables/index.html (accessed 2 February 2009).
233. Warren E, Ward S, Gordois A, Scuffham P. Cost-utility analysis of imatinib mesylate for the treatment of chronic myelogenous leukemia in the chronic phase. Clin Ther 2004;26:1924-33.
234. Kattan MW, Inoue Y, Giles FJ, Talpaz M, Ozer H, Guilhot F, et al. Cost-effectiveness of interferon-alpha and conventional chemotherapy in chronic myelogenous leukemia. Ann Intern Med 1996;125:541-8.
235. Reed SD, Anstrom KJ, Li Y, Schulman KA. Updated estimates of survival and cost effectiveness for imatinib versus interferon-alpha plus low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukaemia. Pharmacoeconomics 2008;26:435-46.
236. Kantarjian HM, Talpaz M, O'Brien S, Jones D, Giles F, Garcia-Manero G, et al. Survival benefit with imatinib mesylate versus interferon-alpha-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia. Blood 2006;108:1835-40.
237. Kantarjian HM, Cortes JE, O'Brien S, Luthra R, Giles F, Verstovsek S, et al. Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-alpha. Blood 2004;104:1979-88.
238. Roy L, Guilhot J, Krahnke T, Guerci-Bresler A, Druker BJ, Larson RA, et al. Survival advantage from imatinib compared with the combination interferon-alpha plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 studies. Blood 2006;108:1478-84.
239. Parmar MKB, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 1998;17:2815-34.
240. Tierney J, Stewart L, Ghersi D, Burdett S, Sydes M. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007;8:16.
241. Garside R, Round A, Dalziel K, Stein K, Royle P. The effectiveness and cost-effectiveness of imatinib in chronic myeloid leukaemia: a systematic review. Health Technol Assess 2002;6(33).
242. Kantarjian H, Cortes J. BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia: using guidelines to make rational treatment choices. J Natl Compr Canc Netw 2008;6:S43-S44.
243. Cervantes F, Lopez-Guillermo A, Bosch F, Terol MJ, Rozman C, Montserrat E. An assessment of the clinicohematological criteria for the accelerated phase of chronic myeloid leukemia. Eur J Haematol 1996;57:286-91.
244. Gordois A, Scuffham P, Warren E, Ward S. Cost-utility analysis of imatinib mesilate for the treatment of advanced stage chronic myeloid leukaemia. Br J Cancer 2003;89:634-40.
245. Liberato NL, Quaglini S, Barosi G. Cost-effectiveness of interferon alfa in chronic myelogenous leukemia. J Clin Oncol 1997;15:2673-82.
246. British Medical Association and Royal Pharmaceutical Society of Great Britain. British national formulary. No. 58, September 2009. London BMA and RPS; 2009.
247. Department of Health. National tariff 2006/07. 2007. URL: www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPoli cyAndGuidance/DH_4127649 (accessed December 2009).
248. Department of Health. NHS reference costs 2006/07. 2008.
249. Kantarjian HM, Shan J, Smith T, Talpaz M, Kozuch P, Rios MB, et al. Response to therapy is independently associated with survival prolongation in chronic myelogenous leukemia in blastic phase. Cancer 2001;92:2501-7.
250. Collett D. Modelling survival data in medical research. 2nd edn. Boca Raton, FL: Chapman & Hall/CRC; 2003.
251. Kantarjian H, O'Brien S, Cortes J, Giles F, Shan J, Rios MB, et al. Survival advantage with imatinib mesylate therapy in chronic-phase chronic myelogenous leukemia (CML-CP) after IFN-{alpha} failure and in late CML-CP, comparison with historical controls. Clin Cancer Res 2004;10:68-75.
252. Sawyers CL, Hochhaus A, Feldman E, Goldman JM, Miller CB, Ottmann OG, et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 2002;99:3530-9.
253. Piazza RG, Magistroni V, Franceschino A, Andreoni F, Tornaghi L, Colnaghi F, et al. The achievement of durable complete cytogenetic remission in late chronic and accelerated phase patients with CML treated with Imatinib mesylate predicts for prolonged response at 6 years. Blood Cells Mol Dis 2009;37:111-15.
254. Palandri F, Iacobucci I, Martinelli G, Amabile M, Poerio A, Testoni N, et al. Long-term outcome of complete cytogenetic responders after imatinib 400 mg in late chronic phase, philadelphia-positive chronic myeloid leukemia: the GIMEMA Working Party on CML. J Clin Oncol 2008;26:106-11.
255. Iacobucci I, Rosti G, Amabile M, Poerio A, Soverini S, Cilloni D, et al. Comparison between patients with philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment. J Clin Oncol 2006;24:454-59.
256. Guilhot F, Larson RA, O'Brien SG, Gathmann I, Druker BJ. Time to complete cytogenetic response (CCyR) does not affect long-term outcomes for patients on imatinib therapy. Blood 2007;110:27.
257. Cortes J, Talpaz M, O'Brien S, Jones D, Luthra R, Shan J, et al. Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate. Clin Cancer Res 2005;11:3425-32.
258. Iacobucci I, Saglio G, Rosti G, Testoni N, Pane F, Amabile M, et al. Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients. Clin Cancer Res 2006;12:3037-42.
259. Marin D, Milojkovic D, Olavarria E, Khorashad JS, de Lavallade H, Reid AG, et al. European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor. Blood 2008;112:4437-44.
260. Kantarjian H, O'Brien S, Shan J, Huang X, Garcia-Manero G, Faderl S, et al. Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia. Cancer 2008;112:837-45.
261. Press RD, Love Z, Tronnes AA, Yang R, Tran T, Mongoue-Tchokote S, et al. BCR-ABL mRNA levels at and after the time of a complete cytogenetic response (CCR) predict the duration of CCR in imatinib mesylate-treated patients with CML. Blood 2006;107:4250-6.
262. de Lavallade H, Apperley JF, Khorashad JS, Milojkovic D, Reid AG, Bua M, et al. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol 2008;26:3358-63.
263. Marin D, Goldman JM, Olavarria E, Apperley JF, Cortes J, Kantarjian H. Transient benefit only from increasing the imatinib dose in CML patients who do not achieve complete cytogenetic remissions on conventional doses. Blood 2003;102:2702-3.
264. Kantarjian HM, Cortes J, O'Brien S, Giles FJ, Albitar M, Rios MB, et al. Imatinib mesylate (STI571) therapy for philadelphia chromosome-positive chronic myelogenous leukemia in blast phase. Blood 2002;99:3547-53.
265. Kantarjian HM, Smith T, O'Brien S, Beran M, Pierce S, Talpaz M, et al. Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-α. Ann Intern Med 1995;122:254-61.
266. Steegman JL, Odriozola J, Rodriguez-Salvanes F, Giraldo P, Garcia-Larana J, Ferro MT, et al. Stage, percentage of basophils at diagnosis, hematologic response within six months, cytogenetic response in the first year: the main prognostic variables affecting outcome in patients with chronic myeloid leukemia in chronic phase treated with interferon-alpha. Results of the CML89 study of the Spanish Collaborative Group on interferon-alpha2a and CML. Haematologica 1999;84:978-87.
267. Bonifazi F, de Vivo A, Rosti G, Guilhot F, Trabacchi E, Hehlmann R, et al. Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders. Blood 2001;98:3074-81.
268. Hehlmann R, Hochhaus A, Berger U, Reiter A. Current trends in the management of chronic myelogenous leukemia. Ann Hematol 2000;79:345-54.
269. Guilhot F, Chastang C, Michallet M, Guerci A, Harousseau JL, Maloisel F, et al. Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group. N Engl J Med 1997;337:223-9.
270. Mahon F-X, Delbrel X, Cony-Makhoul P, Faberes C, Boiron JM, Barthe C, et al. Follow-up of complete cytogenetic remission in patients with chronic myeloid leukemia after cessation of interferon alfa. J Clin Oncol 2002;20:214-20.
271. Schrover RJ, Adena MA, Lourenco RD, Prince HM, Seymour JF, Wonder MJ. Development of a predictive population survival model according to the cytogenetic response rate for patients with chronic myeloid leukemia in the chronic phase. Leuk Lymphoma 2006;47:1069-81.
272. Taylor RS, Elston J. The use of surrogate outcomes in model-based cost-effectiveness analyses: a survey of UK Health Technology Assessment reports. Health Technol Assess 2009;13(8).
273. Quintas-Cardama A, Kantarijan H, Jones D, Shan J, Borthakur G, Thomas D, et al. Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy. Blood 2009;113:6315-21.
274. Anstrom KJ, Reed SD, Allen AS, Glendenning GA, Schulman KA. Long-term survival estimates for imatinib versus interferon-alpha plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia. Cancer 2004;101:2584-92.